secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001816590-25-000085
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Pathways positive Phase 3 COMP005 psilocybin trial meets primary endpoint for TRD
--------------------------------------------------------------------------------

- COMP360 25 mg single dose showed MADRS reduction -3.6 vs placebo (p<0.001) at week 6.
- DSMB chair: no new safety findings; no clinically meaningful imbalance in suicidality.
- 258 participants enrolled across 32 US sites; blinded extension to week 26, open-label to 52.
- COMP006 (568 participants) 26-week data expected H2 2026; company plans FDA discussions.
- First pivotal Phase 3 positive; supports regulatory path for COMP360 in treatment-resistant depression.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/0001816590-25-000085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm
  HTML page:      https://secwatch.observer/filing/0001816590-25-000085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer